Clarus Therapeutics Holdings, Inc. Warrants
CRXTW
CRXTW was delisted on the 30th of August, 2022.
22 hedge funds and large institutions have $3.13M invested in Clarus Therapeutics Holdings, Inc. Warrants in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 8 closing their positions.
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
16% less capital invested
Capital invested by funds: $3.75M → $3.13M (-$613K)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$307K |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$173K |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$106K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$105K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$64.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$116K |
| 2 |
LA
Linden Advisors
New York
|
-$99K |
| 3 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$76.1K |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$76K |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$74K |
CRXTW Hedge Fund Activity: Q3 2021 in Review
22 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) for Q3 2021, worth a combined $3.13M — down 16% from $3.75M a quarter earlier.
Fund positioning in CRXTW was balanced in Q3 2021: 8 funds opened new positions, 8 closed out, 5 added to existing stakes and 8 trimmed.
The largest buyer was Aristeia Capital, opening a new position worth an estimated $307K. The largest seller was Radcliffe Capital Management, cutting an estimated $116K.
- 22 institutional investors held Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $3.13M of Clarus Therapeutics Holdings, Inc. Warrants stock for Q3 2021, down 16% quarter-over-quarter.
- 8 funds opened new Clarus Therapeutics Holdings, Inc. Warrants positions in Q3 2021 and 8 closed out, a net change of 0 holders.
- The largest Clarus Therapeutics Holdings, Inc. Warrants buyer in Q3 2021 was Aristeia Capital, an estimated $307K added.
- The largest Clarus Therapeutics Holdings, Inc. Warrants seller in Q3 2021 was Radcliffe Capital Management, an estimated $116K sold.
Based on aggregated 13F filings for Q3 2021.